Key Takeaways

  • Strand Therapeutics, led by CEO Jake Becraft, developed an RNA genetic medicine that instructs cancer cells to send immune-activating signals.
  • This approach successfully triggered the "abscopal effect" in a Stage 4 melanoma patient, leading to the disappearance of tumors throughout the body.
  • The abscopal effect, a rare phenomenon where local treatment of one tumor causes distant tumors to shrink, has been demonstrated by Strand's injectable drug in a multitude of patients, not just isolated cases.
  • Instead of directly attacking cancer, Strand's therapy programs the cancer itself to "educate" the body's immune system to target all tumors, even those untouched by the initial injection.

When Cancer Teaches the Immune System to Kill Itself

Imagine a Stage 4 melanoma patient, tumors spread throughout their body, facing a grim prognosis. Now imagine those tumors disappearing, not just at the injection site, but everywhere. This is the engineered outcome of Strand Therapeutics' RNA genetic medicine, as explained by CEO Jake Becraft.

Strand's approach is counter-intuitive and powerful. Becraft calls their work “next generation genetic medicines.” Your body runs on proteins. DNA makes RNA, and RNA makes proteins. “The way to actually intervene in disease, the way to get to its core is to create the correct proteins,” Becraft says. Their innovation? They don't just deliver a drug; they deliver instructions. They send RNA directly into cancer cells, programming those cells to produce specific signals. Becraft explains, “What we are doing with our medicine is delivering the instructions into the cancer cells in a way that causes the cancer to basically send its own signal out.”

This internal signaling triggers what doctors call the "abscopal effect." It's a phenomenon where treating one tumor somehow activates the immune system to attack other, untreated tumors elsewhere in the body. For years, this was considered a rare, almost mythical event, a medical unicorn. But Becraft describes a patient whose widespread Stage 4 melanoma tumors vanished after a local injection, a direct result of this engineered abscopal response.

The real shift isn't just one patient. Becraft is clear: “We are to my knowledge one of the first companies, if not the first company to demonstrate a direct injectable drug into the tumor that in a large number of patients, this isn't a one-off.” Strand reliably triggers a systemic immune education. They aren't hoping for a lucky break. The drug activates the immune system at the injected tumor, which then “is activated and educated to go and kill the other tumors.” This move from anecdote to reproducible outcome represents a step forward in cancer treatment.

What to Do With This

Forget the biotech for a moment. Think about this: Strand Therapeutics turned a rare, almost accidental medical phenomenon—the abscopal effect—into a repeatable, engineered outcome for a "multitude of patients." As a founder, your job is similar: find the outlier successes, the "one-off" wins that everyone dismisses as luck, and then reverse-engineer their core mechanism. Dig into those strange customer acquisition spikes, that unexpected viral moment, or the customer who stuck around for years against all odds. What was the internal "RNA instruction" that triggered a disproportionate "immune response" in your market? Design a process to reliably deliver that instruction, even if it feels unconventional, like having your "problem" send its own solution signal.